Frontier IP's portfolio company The Vaccine Group signs option to license agreement with Syva
Why we think this is neutral
This RNS announcement does not contain any of the mandatory news types, such as contract news with revenue, order news with value, or trading update with numbers. It is a general update on a collaboration agreement between Frontier IP's portfolio company The Vaccine Group and Spanish animal health company Syva. While the news is positive for Frontier IP, it does not have a significant immediate impact on the company's financials or share price.
Key Points
- Frontier IP portfolio company The Vaccine Group (TVG) has entered a collaboration with Spanish animal health group Syva to develop a vaccine against Streptococcus suis, a harmful pig disease
- Syva will have an option to negotiate an exclusive worldwide licence for any vaccine developed through the collaboration
- The work builds on previous research by TVG, which has been supported by two Innovate UK grants
Summary
Frontier IP, a specialist in commercialising intellectual property, has announced that its portfolio company The Vaccine Group (TVG) has entered a collaboration with leading Spanish animal health group Syva to develop a vaccine against Streptococcus suis, a widespread and harmful pig disease. Syva will have an option to negotiate an exclusive worldwide licence for any vaccine developed through the collaboration. This builds on work already undertaken by TVG, a University of Plymouth spin out, which has been supported by two Innovate UK grants.